Landmark trial
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617)
Bradley JD, Paulus R, Komaki R, et al. · RTOG
DoseLab summary
Randomized two-by-two factorial phase 3 trial of standard- versus high-dose chemoradiation (with or without cetuximab) for stage III non-small cell lung cancer. The high-dose arm did not improve survival.
Why this is useful
Essential context for conventionally fractionated lung planning: a randomized dose-escalation trial in which the higher dose did not improve outcomes. Its secondary analyses drew attention to cardiac dose.
Reference details
- Title
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617)
- Authors / organization
- Bradley JD, Paulus R, Komaki R, et al. · RTOG
- Publication / protocol
- Lancet Oncol. 2015;16(2):187–199
- Version
- Pending verification
- Year
- 2015
- DOI
- 10.1016/S1470-2045(14)71207-0
- Disease sites
- Lung
- Topics
- Conventional fractionation, Landmark trial, RTOG, Chemoradiation, Heart dose
- Fractionation context
- Conventional (2 Gy per fraction)
- Last reviewed by DoseLab
- Pending verification